General Announcement-Press Release - iXB 401 Achieves 20x Higher Bioavailability Than Rybelsus in Preclinical Study
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.